From my own standpoint, I believe that vaccines have long tampered too much with the body's immune system, so as to favour 'quick fixes' in a world where too few people have adequate nutrition. I favour homoeopathic medicines that treat the patient and restore balance, over allopathic medicines.
The BBC and World Health Organisation refute the claims made by Dr Carrie Madej,
https://www.bbc.co.uk/news/53525002
Coronavirus: False and misleading claims about vaccines debunked
but I note that both are now heavily funded by billionaires who also finance vaccine development, and the BBC has also been known to delete material from public consumption regarding influence of Unum in 'steering' UK Government 'welfare reform' policies.
https://www.mostewartresearch.co.uk/introduction/
Vaccine development is very lucrative.
https://www.wddty.com/news/2020/03/big-pharma-twice-as-profitable-as-any-other-industrial-sector.htmlSo, whatever the relative merits or demerits of Dr Carrie Madej's arguments, I believe it is fair to conclude that the development of these vaccines is designed to perpetutate gross imbalances of wealth, while developers such as those behind Moderna claim to be 'superhuman' themselves.
Researchers at Bentley University compared the revenues and profitability of 35 of the largest drug companies with 357 companies of equivalent size from other industries. Big Pharma twice as profitable as any other industrial sector
About the author:
Bryan Hubbard
The average gross profit margin of a drug company is around 76 percent of revenues compared to just 37 percent of a typical large conglomerate listed on the S&P 500 index.
A typical large pharmaceutical was outpacing a company of similar size operating in a different sector across several financial measures; earnings were 13.8 percent against 7.7 percent for other industry sectors, gross profit margins were 76.5 percent compared to 37.4 percent, and earnings before interest and tax were 29.4 percent against a non-pharmaceutical sector average of 19 percent.
Pharmaceutical profits reduced slightly when research and development costs were added back in, but the findings still raise questions about the price drug companies charge for their products, the researchers say.
